Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Phase 2

Completed

• Conditions: Haemoglobinopathies; Primary Immunodeficiencies; Bone Marrow Failure Syndromes; Inborn Errors of Metabolism
• Interventions: Drug: Treosulfan; Drug: Busilvex

• Registration Number: NCT02349906
• Lead Sponsor: medac GmbH

Brief Summary

The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v. Busulfan, each administered as part of a standardised Fludarabine-containing conditioning regimen and to contribute to a PK model which permits - in conjunction with data comparing Treosulfan and Busulfan in adults with malignant diseases - to extend the use of Treosulfan in the paediatric population by extrapolating efficacy.

Detailed Description

The prospective clinical phase II protocol MC-FludT.16/NM is to be conducted to verify safety and efficacy of Treosulfan-based conditioning compared to Busulfan-based conditioning in paediatric patients. Based on the given clinical experience with either Treosulfan-based or Busulfan-based conditioning in combination with Fludarabine no increased risk for graft failure is expected in paediatric patients. A potential benefit for study patients is expected with respect to a probably low non-haematological toxicity of treatment compared to myeloablative TBI-based conditioning or high-dose Busulfan-based conditioning in combination with Cyclophosphamide.

However, the allogeneic HSCT procedure itself potentially involves serious risks with regard to severe or life-threatening conditions like graft versus host disease (GvHD) and/or infectious complications as well as graft failure.

In summary, the primary goal of this study is to evaluate the Treosulfan-based myeloablative conditioning regimen as an alternative in children and to contribute to the current PK model for Treosulfan to be able to finally give age (or body surface area \[BSA\]) dependent dose recommendations. The treatment regimens given in the protocol MC-FludT.16/NM are based on sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic HSCT of the selected patient population, the risk-benefit assessment seems to be in favour of the study conduct.

Moreover, planned interim analyses will ensure the early identification of unexpected risks. Therefore, the conduct of the protocol MC-FludT.16/NM is considered reasonably justified.

Study Timeline

• Study First Submitted: 2015-01-26
• Study First Submitted QC: 2015-01-26
• Study First Posted: 2015-01-29
• Study Start: 2015-04
• Primary Completion: 2020-05-07
• Study Completion: 2023-04
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-02
• Last Update Posted: 2023-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

1. Non-malignant disease indicated for first myeloablative allogeneic HSCT, including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies and bone marrow failure syndromes.
2. First allogeneic HSCT.
3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as at least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A, -B, -C, -DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is defined as at least 5/6 matches after two digit typing in HLA-A and -B and four digit typing in DRB1 antigens.

Exclusion Criteria

1. Second or later HSCT.
2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood stem cells (PBSC) or less than 5/6 matched cord donor).
3. Preterm newborn infants (<37 weeks gestational age) and term newborn infants aged 0 - 27 days at time of registration.
4. Obese paediatric patients with body mass index weight (kg)/[height (m)]² > 30 kg/m².
5. Diagnosis of Fanconi anaemia and other chromosomal breakage disorders, radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase 4, Cernunnos- X-ray repair cross-complementing protein 4 (XRCC4) like factor (XLF), Nijmegen Breakage Syndrome (NBS)) and Dyskeratosis Congenita.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treosulfan	Treosulfan	One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation. The dose has to be calculated as follows: If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day. If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day. If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day.
Busulfan	Busilvex	Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.

Primary Outcome Measures

Name	Time	Method
Comparative evaluation of freedom from transplant (treatment)-related mortality (TRM), defined as death from any transplant-related cause from the day of first administration of study medication (day -7) until day +100 after HSCT.	day -7 to day +100

Trial Locations

Locations (21)

University Hospital Frankfurt; 🇩🇪 Frankfurt am Main, Germany

S.C. Oncoematologia Pediatrica Fondazione IRCCS Policlinico San Matteo; 🇮🇹 Pavia, Italy

Oncoematologia Pediatrica A.O. di Perugia Ospedale S. Maria della Misericordia; 🇮🇹 Perugia, Italy

Heidelberg University Hospital; 🇩🇪 Heidelberg, Germany

Hannover Medical University, Dep. of Paediatrics, Paediatric Haematology and Oncology; 🇩🇪 Hannover, Germany

Uniwersytecki Szpital Dzieciecy w Krakowie; 🇵🇱 Krakow, Poland

University Hospital Motol, Dep. of Paediatric Haematology and Oncology; 🇨🇿 Prague, Czechia

University of Jena, Department of Pediatrics; 🇩🇪 Jena, Germany

Ulm, University Hospital, Clinic for Children and Adolescents; 🇩🇪 Ulm, Germany

U.O. Oncoematologia Pediatrica Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara; 🇮🇹 Pisa, Italy

Dzieciecy Szpital Kliniczny im. A. Gebali w Lublinie; 🇵🇱 Lublin, Poland

Wroclaw Medical University, Department of Pediatric Hematology/Oncology and BMT; 🇵🇱 Wroclaw, Poland

University Children's Hospital Essen Pediatric stem cell transplantation; 🇩🇪 Essen, Germany

SC Oncoematologia Pediatrica Ospedale Pediatrico Microcitemico "Antonio Cao" A.O. Brotzu; 🇮🇹 Cagliari, Italy

Szpital Uniwersytecki im. dr Antoniego Jurasza; 🇵🇱 Bydgoszcz, Poland

Department of Pediatric Oncology & Hematology, Charite Berlin; 🇩🇪 Berlin, Germany

U.O.C. Oncoematologia Pediatrica Policlinico "G.B. Rossi" - AOUI Verona; 🇮🇹 Verona, Italy

UOC Ematologia ed Oncologia Pediatrica con TMO AOU Policlinico Vittorio Emanuele; 🇮🇹 Catania, Italy

Reparto Trapianti Midollo Osseo Clinica Pediatrica Universitaria Fondazione MBBM-Ospedale San Gerardo; 🇮🇹 Monza, Italy

Ospedale Bambino Gesu Roma; 🇮🇹 Rome, Italy

Ospedale Infantile Regina Margherita Torino; 🇮🇹 Turin, Italy